Clinical Edge Journal Scan

Are family members of early-onset BC patients at risk for discordant early-onset cancers?


 

Key clinical point: Some relatives of women with early-onset breast cancer (BC) may have an increased risk of developing discordant early-onset cancers (other than breast cancers).

Major finding: Among relatives of women with early-onset BC, offspring had a higher risk for any discordant early-onset cancer (standardized incidence ratio [SIR] 1.27; 95% CI 1.03-1.55), siblings' children had an increased risk for early-onset testicular cancer (SIR 1.74; 95% CI 1.07-2.69) and ovarian cancer (SIR 2.69; 95% CI 1.08-5.53), and siblings had an increased risk for early-onset pancreatic cancer (SIR 7.61; 95% CI 1.57-22.23).

Study details: Findings are from an analysis of a population-based cohort including 54,753 relatives from 5562 families of females diagnosed with early-onset BC.

Disclosures: This study was funded by the Cancer Foundation Finland and Academy of Finland. The authors declared no conflicts of interest.

Source: Rantala JNJ et al. Familial aggregation of early-onset cancers in early-onset breast cancer families. Int J Cancer. 2023;153(2):331-340 (Apr 19). Doi: 10.1002/ijc.34538

Recommended Reading

Risk for breast cancer reduced after bariatric surgery
MDedge Hematology and Oncology
Atezolizumab is associated with enhanced response in triple-negative breast cancer
MDedge Hematology and Oncology
Genomic assay changes minds on HER2+ BC treatment
MDedge Hematology and Oncology
HR+ early BC patients could briefly interrupt endocrine therapy to attempt pregnancy
MDedge Hematology and Oncology
Anthracycline+taxane combo reduces BC recurrence more effectively than either drug alone
MDedge Hematology and Oncology
Better lifestyle index scores associated with improved mortality and disease recurrence in high-risk BC
MDedge Hematology and Oncology
Postmastectomy implants did not increase risk for squamous cell carcinoma in BC patients
MDedge Hematology and Oncology
HER2+ early BC: Extent of disease at diagnosis may predict risk for relapse even after pCR
MDedge Hematology and Oncology
125I seed placement before neoadjuvant chemotherapy good marking method for metastatic lymph nodes in BC
MDedge Hematology and Oncology
Anlotinib-chemotherapy combo shows good efficacy and safety in metastatic TNBC
MDedge Hematology and Oncology